The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?-Reference-Cited by-同舟云学术

The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?

Published:2010-05 Issue:2-3 Volume:95 Page:216-228
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Wellman-Labadie Olivier,Zhou Youwen

Publisher

Elsevier BV

Subject

Health Policy

Reference34 articles.

1. Two decades of orphan product development;Haffner;Nature Reviews Drug Discovery,2002

2. Orphan drug policies: implications for the United States. Canada and developing countries;Cheung;Health Law Journal,2004

3. Clinical research for rare disease: opportunities, challenges and solutions;Griggs;Molecular Genetics and Metabolism,2009

4. Development of orphan vaccines: an industry perspective;Lang;Emerging Infectious Diseases,1999

5. The Orphan Drug Act. Implementation and Impact. United States Department of Health and Human Services. Office of Inspector General; May 2001. http://oig.hhs.gov/oei/o.asp#orphan_drug.

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea;Journal of Pharmaceutical Policy and Practice;2024-06-05

2. Exploring regulatory flexibility to create novel incentives to optimize drug discovery;Frontiers in Medicine;2024-05-13

3. 2023 in review: FDA approvals of new medicines;Drug Discovery Today;2024-05

4. Global Pipeline of Innovative Medicinal Products: A Narrative Review;Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation;2024-02-27

5. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022;Scientific Reports;2024-02-09